Topic: cosmetic treatments
AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.
Merz has made two separate investments in its Dessau sites, one for its branded cosmetic drug production and one for its CDMO operations.
Rumor has it that several companies are in talks to buy Daiichi's over-the-counter drugs business, which could fetch $900 million.
Ahead of an aesthetics market battle between Evolus' Jeuveau and Allergan's Botox, Evolus hosted doctors at a conference in Cancun, Mexico.
The moment Allergan has been dreading has arrived. Evolus has snagged its OK for a rival to Allergan’s lead moneymaker, Botox.
Merz Americas hopes to grab cosmetic injection share with two new ad campaigns that push awareness of options other than market leader Botox.
The deal follows a flurry of consumer deals and comes as J&J's beauty products have been delivering strong growth, thanks in part to Ci:z.
The FDA has banned products from an Australian company's plant in Guangzhou, China, and cited it with “significant violations” of cGMP regulations saying that it did not do enough to test its active ingredients and products before they were shipped to the U.S.